In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Nivolumab, also named Opdivo, is a monoclonal antibody used to treat advanced non-small cell lung cancer (NSCLC) by inhibiting a cellular pathway called programmed death-1(PD-1).
Nivolumab binds to PD-1 which is on the surface of T cells, thereby blocking the immunosuppressive signaling pathway triggered by PD-1/PD-2 and restoring the antitumor function of T cells.
Nivolumab binds PD-1 with high specificity , and nivolumab can effectively inhibit PD-1 interact with its ligands (PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nmol/L, respectively). In CHO cells, using FACS to evaluate ligand binding to PD-1, there was no obvious difference between nivolumab-mediated inhibition of PD-1 binding to PD-L1 (IC50 value of 1.04 nmol/L) and PD-L2 (IC50 value of 0.97 nmol/L). Moreover, when lack of antigen or T-cell receptor stimulus, nivolumab had no stimulatory effect and couldn’t cause nonspecific lymphocyte activation .
In cynomolgus monkey model with 10 and 50 mg/kg Nivolumab (i.v.), serum nivolumab seems to be no obvious change and no substantial sex differences. Treated with 50 mg/kg nivolumab, T4 and TSH levels were unchanged but T3 had a reversible 28% decrease in females, and in males there were no changes in T3, T4 or TSH levels . Nivolumab might lack toxicity in monkeys, but the toxicity had been observed in human clinical trials, nivolumab had had a favorable safety profile in a phase I trial . A problem worth studying is that in PD-1-deficient mice observed pneumonitis which bred onto the MRL genetic background rather than other genetic backgrounds .
 Sundar R, Cho B C, Brahmer J R, et al. Nivolumab in NSCLC: latest evidence and clinical potential [J]. Therapeutic Advances in Medical Oncology, 2015, 7(2):85-96.
 Wang C, Thudium K B, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates [J]. Cancer Immunol Res, 2014, 2(9):846-856.
|Physical Appearance||A colorless liquid (10 mg/ml in Nivolumab formulation)|
|Storage||Store at -20°C|
|Synonyms||BMS-936558; ONO-4538; MDX-1106|
|Shipping Condition||Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.|